Albertsson-Wikland K
Department of Paediatrics, University of Göteborg, Gothenburg, Sweden.
Acta Paediatr Suppl. 1993 Sep;82 Suppl 391:75-8. doi: 10.1111/j.1651-2227.1993.tb12934.x.
The auxological characteristics and the response to growth hormone (GH) treatment of children with idiopathic short stature were studied, using the database of the Kabi Pharmacia International Growth Study. Pretreatment data from a total of 271 children were analysed. The children were selected for a birth weight above -2 SDS. The correlation coefficient of birth weight SDS and birth length SDS was 0.51, compared with 0.72 for the reference population. Median length at birth was -0.6 SDS, which fell to -2.5 SDS by 3 years of age. Thereafter, there was no further loss in height SDS. The response to GH treatment was studied in 222 of these prepubertal children who were given six or seven injections/week over a 3-year period. During this time, the median height SDS increased from -2.5 to -1.5, with those children receiving more than 0.65 IU/kg/week having a greater gain in height SDS than those on 0.5 IU/kg/week or less. The degree of bone age delay did not appear to influence the response to GH therapy.
利用卡比- Pharmacia国际生长研究数据库，对特发性身材矮小儿童的体格学特征及生长激素（GH）治疗反应进行了研究。分析了总共271名儿童的治疗前数据。这些儿童入选标准为出生体重高于-2 SDS。出生体重SDS与出生身长SDS的相关系数为0.51，而参考人群为0.72。出生时身长中位数为-0.6 SDS，到3岁时降至-2.5 SDS。此后，身高SDS没有进一步下降。在这些青春期前儿童中的222名中研究了GH治疗反应，他们在3年期间每周接受6或7次注射。在此期间，身高SDS中位数从-2.5增加到-1.5，每周接受超过0.65 IU/kg的儿童比每周接受0.5 IU/kg或更少的儿童身高SDS增加更多。骨龄延迟程度似乎不影响对GH治疗的反应。
